Gokool, S.; Townson, S.; Freeman, A.; Siemienski-Kleyn, J.; Zubrzycki, J.; Tagboto, S.; Hübner, M.P.; Scandale, I. Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia. Pharmaceutics2024, 16, 210.
Gokool, S.; Townson, S.; Freeman, A.; Siemienski-Kleyn, J.; Zubrzycki, J.; Tagboto, S.; Hübner, M.P.; Scandale, I. Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia. Pharmaceutics 2024, 16, 210.
Gokool, S.; Townson, S.; Freeman, A.; Siemienski-Kleyn, J.; Zubrzycki, J.; Tagboto, S.; Hübner, M.P.; Scandale, I. Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia. Pharmaceutics2024, 16, 210.
Gokool, S.; Townson, S.; Freeman, A.; Siemienski-Kleyn, J.; Zubrzycki, J.; Tagboto, S.; Hübner, M.P.; Scandale, I. Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia. Pharmaceutics 2024, 16, 210.
Abstract
Onchocerciasis treatment and control relies mainly on the use of ivermectin which has high activity against the microfilarial stage of Onchocerca volvulus but limited activity against the long lived, tissue dwelling adult nematodes. As this neglected tropical disease has now been targeted for elimination there is an urgent need for new drugs to combat these parasites, ideally with macrofilaricidal activity. In this study we have examined the anti-Onchocerca activity of a range of existing FDA approved drugs with a view to repurposing, which can lead to rapid and relatively inexpensive development. From the Pharmakon-1600 library, 106 drugs were selected and tested against O. gutturosa adult male parasites using a concentration of 1.25 x 10-5 M in an in vitro 5-day standard assay to assess motility and viability (using MTT/formazan colorimetry). The findings revealed that 44 drugs produced marginal/moderate activity (50-99% motility and/or MTT reductions) including cefuroxime sodium, methenamine, primaquine phosphate, rivastigmine tartrate, while 23 drugs produced good activity (100% motility reductions and significant MTT reductions), including atovaquone, isradipine, losartan, rifaximin, cefaclor and pyrantel pamoate. Although this study represents only a first step, some of the identified hits indicate there are potential anti-Onchocerca drug candidates worthy of further investigation.
Keywords
Onchocerciasis; drug discovery; anthelmintics; O. gutturosa; motility and MTT inhibition; FDA approved drugs
Subject
Biology and Life Sciences, Parasitology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
